Valuation: Eli Lilly and Company

Capitalization 84TCr 72TCr 66TCr 62TCr 1,16200Cr 78,18500Cr 1,18600Cr 7,77500Cr 3,04200Cr 37,54500Cr 3,15500Cr 3,08800Cr 1,33,77400Cr P/E ratio 2026 *
27.6x
P/E ratio 2027 * 23.2x
Enterprise value 86TCr 73TCr 68TCr 64TCr 1,18400Cr 79,66400Cr 1,20900Cr 7,92200Cr 3,10000Cr 38,25600Cr 3,21400Cr 3,14600Cr 1,36,30400Cr EV / Sales 2026 *
10.5x
EV / Sales 2027 * 8.82x
Free-Float
99.81%
Yield 2026 *
0.71%
Yield 2027 * 0.8%
1 day-1.65%
1 week+0.42%
Current month+2.14%
1 month-6.04%
3 months-11.67%
6 months+12.72%
Current year-12.58%
1 week 898.45
Extreme 898.4501
963.94
1 month 877.11
Extreme 877.11
1,003.22
Current year 877.11
Extreme 877.11
1,133.95
1 year 623.78
Extreme 623.78
1,133.95
3 years 367.35
Extreme 367.35
1,133.95
5 years 178.58
Extreme 178.5779
1,133.95
10 years 64.18
Extreme 64.18
1,133.95
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2017
Director of Finance/CFO 49 09/09/2024
Chief Tech/Sci/R&D Officer 52 -
Director TitleAgeSince
Director/Board Member 65 01/01/2005
Director/Board Member 69 01/04/2009
Director/Board Member 54 12/12/2011
Change 5d. change 1-year change 3-years change Capi.($)
-1.65%+0.42%+28.27%+158.07% 84TCr
-1.18%-1.88%+57.16%+45.16% 57TCr
-2.10%-0.43%+18.79%+28.85% 37TCr
-0.09%0.00%+30.43%+16.21% 32TCr
-0.30%-0.56%+52.18%+30.95% 32TCr
-1.03%+0.46%+53.35%+7.94% 30TCr
-0.34%-1.17%+41.43%+40.20% 29TCr
-1.29%+0.89%+22.74%+39.61% 19TCr
-2.18%-0.52%+34.12%+68.39% 17TCr
+1.07%+1.58%-42.74%-55.49% 17TCr
Average -0.91%+0.41%+29.57%+37.99% 35.46TCr
Weighted average by Cap. -1.08%+0.08%+34.15%+58.86%

Financials

2026 *2027 *
Net sales 8.17TCr 6.96TCr 6.44TCr 6.07TCr 11TCr 7,60100Cr 12TCr 76TCr 30TCr 3,65000Cr 31TCr 30TCr 13,00500Cr 9.5TCr 8.09TCr 7.49TCr 7.05TCr 13TCr 8,83100Cr 13TCr 88TCr 34TCr 4,24100Cr 36TCr 35TCr 15,11000Cr
Net income 3.04TCr 2.59TCr 2.4TCr 2.26TCr 4.2TCr 2,82700Cr 4.29TCr 28TCr 11TCr 1,35700Cr 11TCr 11TCr 4,83600Cr 3.62TCr 3.08TCr 2.85TCr 2.69TCr 5.01TCr 3,36700Cr 5.11TCr 33TCr 13TCr 1,61700Cr 14TCr 13TCr 5,76100Cr
Net Debt 1.59TCr 1.35TCr 1.25TCr 1.18TCr 2.2TCr 1,47900Cr 2.24TCr 15TCr 5.76TCr 71TCr 5.97TCr 5.84TCr 2,53100Cr -301.73Cr -257.05Cr -237.89Cr -223.99Cr -417.21Cr -28TCr -425.76Cr -2.79TCr -1.09TCr -13TCr -1.13TCr -1.11TCr -48TCr
Logo Eli Lilly and Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (74%): products for treating osteoporosis, diabetes, and growth problems; - oncology (14.4%); - immunology diseases (8.1%); - neurology (2.1%): primarily drugs used in treating depression and schizophrenia; - other (1.4%). Net sales are distributed geographically as follows: the United States (66.7%), Europe (17.7%), Japan (3.2%), China (3%) and other (9.4%).
Employees
50,000
Date Price Change Volume
10/26/10 939.47 $ -1.65% 19,58,925
09/26/09 955.19 $ +0.20% 16,72,549
08/26/08 953.30 $ +2.39% 25,67,998
07/26/07 931.09 $ +0.43% 27,26,863
06/26/06 927.06 $ -0.91% 18,21,082
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
939.47USD
Average target price
1,209.69USD
Spread / Average Target
+28.76%

Quarterly revenue - Rate of surprise